An interventional study of active Transcranial Magnetic Stimulation and sham Transcranial Magnetic Stimulation in Stress, Psychological, Sleep Initiation and Maintenance Disorders and Transcranial Magnetic Stimulation, sponsored by Xijing Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-10-23.
Sponsored by Xijing Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Stress, Psychological with a site in China — 9 open to participants now, 11 under way, none of them phase 3. Stress, Psychological · China.
Among the 28 studies in Stress, Psychological with a site in China, this one is the 17th largest by planned enrollment of the 19 interventional ones that give a count, is one of 6 that started in 2024, is one of 18 with no phase, reaches primary completion later than 5 of the 10 other live ones, and was the 17th registered.
853 studies on the registry are indexed under Stress, Psychological; 141 are open to participants now.
Browse Stress, Psychological studies →9 of the 28 studies in Stress, Psychological with a site in China are open now. Recruiting first, the newest first:
Peking University · Sites in China
Ages 10–18 · Healthy volunteers
Universiti Sains Malaysia · Sites in China
Healthy volunteers
Shengjing Hospital · Sites in China
Ages 18+ · Women only
Second Xiangya Hospital of Central South University · Sites in China
Ages 18+
DiproBio (Shanghai) Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 74 Stress, Psychological studies recruiting now, 34 (46%) set no upper age limit and 36 (49%) stop at 75 or younger; 13 take children under 18; 49 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 6 started in 2024.
This study's planned enrollment of 60 is below the median of 84 across 698 interventional studies indexed under Stress, Psychological.
Median enrollment 126 across the 19 interventional studies, 311 across the 9 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 28 have an industry lead sponsor. The 10 most frequent:
Xijing Hospital is the lead sponsor of 475 studies on the registry; 158 are open to participants now.
Xijing Hospital has 1 study filed under Stress, Psychological — fewer than ten, so there is no comparison to draw.
1 of the studies in Stress, Psychological with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07940283DiproBio (Shanghai) Co., Ltd.Effects of a Combination of Bifidobacterium Longum Subsp. Longum Strains on Stress and Related Health Outcomes in Young Adult | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies in Stress, Psychological with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind controlled study that recruited patients with insomnia problems after suffering a stressful event to undergo individualized transcranial magnetic stimulation
This is a randomized, double-blind controlled study that will recruit patients who have experienced a stressful event and currently exhibit severe sleep problems for transcranial magnetic stimulation. They will be randomly assigned to the trial and control groups and will receive 5 consecutive days of continuous theta-wave stimulation, and before and after the treatment they will be assessed on clinical scales and undergo magnetic resonance examinations as well as sleep monitoring.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The most relevant site of functional connectivity between vlPFC-VTA will be targeted for continuous theta burst stimulation
Device: active Transcranial Magnetic Stimulation
The most relevant site of functional connectivity between vlPFC-VTA will be targeted for sham continuous theta burst stimulation
Device: sham Transcranial Magnetic Stimulation
Based on each individual's MRI data, individualized stimulation targets will be found, and then this will be used for stimulation for 5 consecutive days.
Based on each individual's MRI data, individualized stimulation targets will be found, and then this will be used for sham stimulation for 5 consecutive days.
Change in Pittsburgh sleep quality index (PSQI) scores from baseline to post-treatment
The Pittsburgh Sleep Quality Index, compiled in 1989 by Dr. Buysse, a psychiatrist at the University of Pittsburgh, and others. It is suitable for patients with sleep disorders to evaluate the quality of their sleep, as well as for the general population to assess the quality of their sleep. The scale consists of 9 questions, of which the first 4 are fill-in-the-blanks and the last 5 are multiple-choice (question 5 contains 10 sub-questions) Change = (treatment day 5 Score -Baseline Score).
Time frame: Baseline and treatment day 5
Change in Posttraumatic Stress Disorder Check List for Diagnostic and Statistical Manual of Mental Disorders-5 scores from baseline to treatment day 5
Posttraumatic Stress Disorder Check List for Diagnostic and Statistical Manual of Mental Disorders-5(PCL-5) is a validated, self-reported instrument assessing PTSD symptom severity over the past week or month period .Possible scores range from 0 to 80 . Change = (treatment day 5 Score -Baseline Score).
Time frame: Baseline and treatment day 5
Change in Stanford Acute Stress Reaction Questionnaire (SASRQ) scores from baseline to treatment day 5
The Stanford Acute Stress Reaction Questionnaire (SASRQ) is a commonly used international instrument for assessing acute stress disorders. It consists of 5 dimensions, including alertness, dissociation, avoidance, re-experiencing, and impairment of social functioning, with a total of 30 items, ranging from "not experiencing" to "always experiencing". A total of 30 items, ranging from "no experience" to "always experience", were assigned a score of 0 to 5, with a total score of 0 to 150. The higher the total score, the more severe the acute stress disorder, with a score of ≥40 suggesting a moderate likelihood of acute stress disorder. Change = (treatment day 5 Score -Baseline Score).
Time frame: Baseline and treatment day 5
Change in Hamilton Depression Scale(HAMD-17)scores from baseline to treatment day 5 Score
Hamilton Depression Scale(HAMD-17) is a commonly used clinical evaluation standard for the severity of depressive symptoms. There are 17 items in total, which can be scored before and after treatment to evaluate the severity of the disease and the treatment effect.Possible scores range from 0 to 52 and the higher the score, the worse the symptom. Change = (treatment day 5 Score -Baseline Score).
Time frame: Baseline and treatment day 5
Change in Hamilton Anxiety Scale scores from baseline to treatment day 5 Score
Hamilton Anxiety Scale (HAMA)is suitable for assessing the severity of anxiety symptoms. It has 14 items and adopts a 5-level scoring method of 0-4 points.Possible scores range from 0 to 56 and the higher the score, the worse the symptom. Change = (treatment day 5 Score -Baseline Score).
Time frame: Baseline and treatment day 5
Change in Posttraumatic Stress Disorder Check List for Diagnostic and Statistical Manual of Mental Disorders-5 scores from baseline to 28 days after the end of treatment
Posttraumatic Stress Disorder Check List for Diagnostic and Statistical Manual of Mental Disorders-5(PCL-5) is a validated, self-reported instrument assessing PTSD symptom severity over the past week or month period .Possible scores range from 0 to 80 . Change = (28 days after the end of treatment Score -Baseline Score).
Time frame: Baseline and 28 days after the end of treatment
Change in Stanford Acute Stress Reaction Questionnaire (SASRQ) scores from baseline to 28 days after the end of treatment
The Stanford Acute Stress Reaction Questionnaire (SASRQ) is a commonly used international instrument for assessing acute stress disorders. It consists of 5 dimensions, including alertness, dissociation, avoidance, re-experiencing, and impairment of social functioning, with a total of 30 items, ranging from "not experiencing" to "always experiencing". A total of 30 items, ranging from "no experience" to "always experience", were assigned a score of 0 to 5, with a total score of 0 to 150. The higher the total score, the more severe the acute stress disorder, with a score of ≥40 suggesting a moderate likelihood of acute stress disorder. Change = (28 days after the end of treatment Score -Baseline Score).
Time frame: Baseline and 28 days after the end of treatment
Change in Hamilton Depression Scale(HAMD-17)scores from baseline to 28 days after the end of treatment
Hamilton Depression Scale(HAMD-17) is a commonly used clinical evaluation standard for the severity of depressive symptoms. There are 17 items in total, which can be scored before and after treatment to evaluate the severity of the disease and the treatment effect.Possible scores range from 0 to 52 and the higher the score, the worse the symptom. Change = (28 days after the end of treatment Score -Baseline Score).
Time frame: Baseline and 28 days after the end of treatment
Change in Hamilton Anxiety Scale scores from baseline to 28 days after the end of treatment
Hamilton Anxiety Scale (HAMA)is suitable for assessing the severity of anxiety symptoms. It has 14 items and adopts a 5-level scoring method of 0-4 points.Possible scores range from 0 to 56 and the higher the score, the worse the symptom.
Time frame: Baseline and 28 days after the end of treatment
Plan to share: No
Start is estimated for Nov 2024; primary completion for Dec 2025, 13 months later.
Of 462 non-industry interventional studies with no phase under Stress, Psychological, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 13 months is close to that.
Counting every sponsor, half of 475 studies reached it within 13 months; a quarter within 5 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.